Intensive care medicine

2019-20 coronavirus outbreak

Asthma

Betacoronavirus

Virology

Receptor

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Outbreak

Montelukast

Coronavirus disease 2019 (COVID-19)

Immunology

Oxidative stress

Cytokine

Inflammation

Infectious disease (medical specialty)

Internal medicine

Pharmacology

Coronavirus Infections

Antagonist

Medicine

Leukotriene

Pandemic

Receptor antagonist

Disease

Medical Hypotheses

It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.

As a potential treatment of COVID-19: Montelukast